23349
document
[ A randomized study of prophylactic intravesical instillation of pirarubicin ( THP ) prior to transurethral resection of superficial bladder cancer ] . A prospective randomized study was conducted to evaluate the efficacy of prophylactic intravesical instillation of pirarubicin ( THP ) prior to transurethral resection ( TUR ) of superficial bladder cancer . A total of 63 patients were randomized into two groups , the THP group and the control group . In the THP group , 30 mg of THP dissolved in 50 ml saline was administered 4 times intravesically for 4 consecutive days before TUR . In the control group , no instillation was performed before TUR . The patients were followed by cystoscopy and urinary cytology every 3 months . The non-recurrence rates in the THP group and control group were 54.1 % versus 37.6 % at 1 year and 40.4 % versus 26.8 % at 2 years , respectively ( P = 0.086 ) . Time to recurrence for tumors larger than 1 cm was significantly longer in the THP group ( P = 0.0137 ) . Time to recurrence for single and grade 1+2 tumors tended to be longer in the THP group ( P = 0.09 , P = 0.079 ) . No significant adverse effects were observed in any patient . Our findings suggest that intravesical THP instillation prior to TUR would be effective for patients with single , low grade lesions larger than 1 cm of superficial bladder cancer .
23350
Intervention_Pharmacological
pirarubicin ( THP )
23351
Intervention_Pharmacological
intravesical instillation of pirarubicin ( THP )
23352
Intervention_Surgical
transurethral resection
23353
Intervention_Pharmacological
THP
23354
Intervention_Pharmacological
50 ml saline
23355
Intervention_Control
no instillation was performed before
23356
Intervention_Surgical
TUR
23357
Intervention_Control
.
23358
Outcome_Physical
superficial bladder cancer
23359
Outcome_Physical
transurethral resection ( TUR ) of superficial bladder cancer
23360
Outcome_Other
.
23361
Outcome_Other
non-recurrence rates
23362
Outcome_Physical
Time to recurrence for tumors larger than 1 cm
23363
Outcome_Physical
Time to recurrence for single and grade 1+2 tumors
23364
Outcome_Adverse-effects
adverse effects
23365
Outcome_Other
effective
23366
Outcome_Physical
single , low grade lesions larger than 1 cm
23367
Outcome_Physical
superficial bladder cancer